Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Granger

Showing results (711-720 of 1,253) with videos related to

Pageof 126
Sort By:
Journal of the American College of Cardiology|August 1, 1996
Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: results in 16,521 patientsE D Peterson, W R Hathaway, K M Zabel, et al.
Circulation. Cardiovascular Quality and Outcomes|September 3, 2010
Impact of a statewide ST-segment-elevation myocardial infarction regionalization program on treatment times for women, minorities, and the elderlySeth W Glickman, Christopher B Granger, Fang-Shu Ou, et al.
American Heart Journal|July 12, 2011
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction"John K French, Paul W Armstrong, Eric Cohen, et al.
American Heart Journal|December 16, 2014
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialChristopher B Granger, Renato D Lopes, Michael Hanna, et al.
Journal of Cardiovascular Translational Research|August 15, 2015
A Guide for a Cardiovascular Genomics Biorepository: the CATHGEN ExperienceWilliam E Kraus, Christopher B Granger, Michael H Sketch, et al.
European Heart Journal|January 18, 2006
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomesAndrés Orlandini, Rafael Díaz, Daniel Wojdyla, et al.
Circulation|August 20, 2003
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trialKenneth W Mahaffey, Christopher B Granger, Jose C Nicolau, et al.
Circulation. Cardiovascular Quality and Outcomes|May 17, 2012
Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insightsSean van Diepen, Petr Widimsky, Renato D Lopes, et al.
The American Journal of Cardiology|September 29, 2005
Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events)Michael J Lim, Kim A Eagle, Joel M Gore, et al.
The New England Journal of Medicine|October 27, 1994
Use of medical resources and quality of life after acute myocardial infarction in Canada and the United StatesD B Mark, C D Naylor, M A Hlatky, et al.
Pageof 126

Showing results (711-720 of 1,253) with videos related to

Sort By:
Pageof 126
Journal of the American College of Cardiology|August 1, 1996
Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: results in 16,521 patientsE D Peterson, W R Hathaway, K M Zabel, et al.
Circulation. Cardiovascular Quality and Outcomes|September 3, 2010
Impact of a statewide ST-segment-elevation myocardial infarction regionalization program on treatment times for women, minorities, and the elderlySeth W Glickman, Christopher B Granger, Fang-Shu Ou, et al.
American Heart Journal|July 12, 2011
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction"John K French, Paul W Armstrong, Eric Cohen, et al.
American Heart Journal|December 16, 2014
Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialChristopher B Granger, Renato D Lopes, Michael Hanna, et al.
Journal of Cardiovascular Translational Research|August 15, 2015
A Guide for a Cardiovascular Genomics Biorepository: the CATHGEN ExperienceWilliam E Kraus, Christopher B Granger, Michael H Sketch, et al.
European Heart Journal|January 18, 2006
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomesAndrés Orlandini, Rafael Díaz, Daniel Wojdyla, et al.
Circulation|August 20, 2003
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trialKenneth W Mahaffey, Christopher B Granger, Jose C Nicolau, et al.
Circulation. Cardiovascular Quality and Outcomes|May 17, 2012
Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insightsSean van Diepen, Petr Widimsky, Renato D Lopes, et al.
The American Journal of Cardiology|September 29, 2005
Treating patients with acute coronary syndromes with aggressive antiplatelet therapy (from the Global Registry of Acute Coronary Events)Michael J Lim, Kim A Eagle, Joel M Gore, et al.
The New England Journal of Medicine|October 27, 1994
Use of medical resources and quality of life after acute myocardial infarction in Canada and the United StatesD B Mark, C D Naylor, M A Hlatky, et al.
Pageof 126